[TREND1]

Revenue=$ 246.05M

[TREND1]

Market Cap = .639 B

[starkd748]

What a piece of shit company...No trades today...Lmfao

[starkd748]

Chinese medicine at its finest it works so well you change nationalities...For an added touch you even get the kinky to match....


https://www.sciencetimes.com/articles/25397/20200420/chinese-doctors-coronavirus-victims-find-skin-turning-black-due-to-liver-damage-and-certain-medications.htm

[starkd748]

Nobody wants poison injected in them not even the Chinese lmfao...

https://nypost.com/2020/04/21/chinese-doctors-skin-turns-dark-after-coronavirus-recovery/

Those guys went from Being Chinese to another nationality over night.....
Hahahaha

[Stock_Barber]

Is it, or does it just not trade much?

[makinezmoney]

$SVA: Just saw it .... but its halted ??????






GO $SVA

[Stock_Barber]

Sinovac being featured on CNBC right now!

[john12]

does anyone know when the buyout is supposed to be finished by sinobioway ?

[Belugas]

Sinovac Biotech to Supply Flu Vaccine in Beijing

06:45 AM EDT, 07/23/2014 (MT Newswires) -- Sinovac Biotech (SVA) Wednesday said it has been selected by the Beijing Centers for Disease Control and Prevention to supply seasonal flu vaccine in Beijing. The Beijing CDC plans to order a minimum of 1.2 million doses of the seasonal flu vaccine this year from four domestic vaccine manufacturers for its vaccination campaign.

The Chinese biopharmaceutical company supplied approximately 400,000 doses of Anflu for the influenza vaccination campaign in Beijing in 2013.

[Belugas]

Sinovac Biotech Selected As Sole Provider Of Hepatitis A Vaccine In Beijing Program

07:28 AM EDT, 07/21/2014 (MT Newswires) -- Sinovac Biotech (SVA) has been selected by the Beijing Health Bureau as the sole supplier of inactivated hepatitis A vaccine in pre-filled syringe dosage to the Expanded Program of Immunization (EPI) for Beijing. The tender is valued at approximately 16 million RMB.

The vaccines purchased by the Beijing Health Bureau will be used for the period from 2014 to 2016. The company expects to begin delivery in the coming months based upon demand.

Shares of SVA are at $5.60 with a 52-week range of $3.80 - $8.14.

[Belugas]

The Department of Disease Control (DDC) is using Chanthaburi as a pilot province for a campaign against hand, foot and mouth disease (HFMD) after more infections were found compared to last year.

DDC Spokesperson Dr Supamit Chunsuttiwat paid a visit to the child development center of Tambon Phlio, Laem Sing district, Chanthaburi province, to preside over the launch of an HFMD prevention campaign. Under the project, local childcare centers, kindergartens and communities will collaborate to instill hygienic habits among children and keep an eye out for HFMD infections.

As the rainy season had arrived, Dr Supamit warned that the cool, humid condition was conducive to the growth of HFMD virus, whereas children were more susceptible to the disease due to a weaker immune system. Therefore, he indicated an urgent need to implement preventive measures.

Caregivers and teachers are being encouraged to make sure that children under their supervision wash their hands regularly and refrain from sharing personal belongings. If a child is found to have HFMD symptoms, he or she should be separated from the others immediately and be allowed time to fully recuperate at home.

Based on the statistics from the Bureau of Epidemiology, from January 1 to June 22 this year, almost 20,000 HFMD cases have been found across the country, an increase of 16 percent from the same period of last year. Most of the patients were in the age range of 1-3 years. The infection rate is expected to continue rising. - See more at: http://thainews.prd.go.th/centerweb/newsen/NewsDetail?NT01_NewsID=WNSOC5707010010013#sthash.9qMVPE6J.dpuf

[tradewithzen]

By Jeff Pierce

SVA has been on a tear since 2012 and has recently pulled back to work off some of it's overbought condition. While there is a risk of this pulling back further, I think now is a good time to initiate a starter position as this could retest it's highs in the coming months. I like the position of the RSI here and as it gets closer to 40. Typically that is an area after a big run-up it finds support. Keep this on your watchlist.



After a bit of a rough patch in April we're starting to get back on trade inside tradewithZEN. I've been trading very light in May during this recent rally as my long term timing signals turned lower in March, but this melt up we've seen may be changing that. If you'd like to gain access to my private twitter feed with daily updates you can do so at http://tradewithzen.com. Here are my trading results since inception last June.

[Belugas]

Surging hand-foot-mouth disease in Beijing

Beijing saw an outbreak of hand-foot-mouth disease with more than 2,600 cases reported per week from May 26 to June 22, said the capital’s disease prevention center on Sunday.

In the four consecutive weeks during the period, the number of weekly reported hand-foot-mouth cases increased from 2,645 to 3,013 in Beijing, said the Beijing Disease Prevention and Control Center.

The cases were more than the same period last year, but the critical or death cases were almost the same, said the municipal health authorities.

Hand-foot-mouth disease is a viral illness that usually affects infants and children younger than five years old. The disease starts with a slight fever followed by blisters and ulcers in the mouth and rashes on the hands and feet. The virus is usually transmitted through digestive and respiratory systems or through intimate contact.

http://www.globaltimes.cn/content/868034.shtml

[rawman]

SWEET!

[Belugas]

Sinovac Announces Favorable Reduction in Value Added Tax Rate

Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the value added tax (or "VAT") rate applied to the sales of Sinovac's vaccine products will be reduced to 3% from the current rate of 6%, according to a joint notice on reducing and unifying the value added tax (VAT) rate published by the Ministry of Finance of China and State Administration of Taxation of China. The notification will become effective July 1, 2014.

Mr. Weidong Yin, Sinovac's CEO and President commented, "The notification is favorable news for Sinovac. We expect this new policy will beneficially impact our future financial results including total sales and net income as sales revenue is recognized as the invoiced value of products sold minus VAT."

[Belugas]

Sinovac IR Director Explains Massive Revenue Opportunity

http://news.yahoo.com/exclusive-sinovac-ir-director-explains-144600368.html

[surf1944]

7:05AM Sinovac Biotech receives Jiangsu Province tender award to supply inactivated hepatitis vaccine Healive under expanded immunization program (SVA) 5.70 : Co announced that it has been selected by the Jiangsu Centers for Disease Control and Prevention to supply the Company's inactivated hepatitis A vaccine, Healive, under the Expanded Program of Immunization in 2014 to the pediatric population in Jiangsu Province. The total volume of the tender is up to 1.8 million doses. As one of the two selected suppliers, Sinovac will supply 900,000 doses of Healive to Jiangsu province.

[mighty face]

what does that means?
my english is not so good.
first go down and than back up until ?$

[TR4GEDY]

I'm just looking for a quick trade nothing else could care less what this company does lol

[rawman]

I've been long SVA for several years and, with the recent run-up, can't disagree with the logic. A pullback would not be a shock. One caution...this is the time of year the WHO or some other agency might identify the annual flu threats. IMO, with anything unusual, i.e. a new strain, found in China, SVA could easily add 50%. It's done a short-term double at least a couple of times in the past.

[TR4GEDY]

Not down but a nice pull back maybe fill the gap this week..

[mighty face]

you think SVA is going down?

[TR4GEDY]

Looking good for a short this week...

[Penny Roger$]

~ $SVA ~ Daily Par Sar Buy Signal ~ Criteria alert triggered during a recent trading session!

$SVA has just triggered the "Parabolic SAR Buy Signals" scan criteria at Stockcharts.com
~ http://tinyurl.com/SAR-BUY ~







For a more in Depth study and DD profile, similar to the one contained in this link: ~ http://tinyurl.com/DDexample ~
Click the following link and type ticker or brief message asking me about the DD: ~ http://tinyurl.com/GET-THE-DD ~

What does the scan "Parabolic SAR Buy Signals" mean? Below is an image example and study link.
~ http://stockcharts.com/school/doku.php?id=chart_school:technical_indicators:parabolic_sar ~


To find other similar posts of "SVA" utilize the links that follow.
Search MACDgyver's "Parabolic SAR Buy Signals" posts: ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=ParSarBuyScan ~
Search MACDgyver's posts for symbol "SVA": ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=SVA ~
Search Ihub for "SVA" posts: ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=SVA ~


For more in depth training and information visit Chartschool on the Stockcharts page.
~ http://stockcharts.com/school/doku.php?id=chart_school ~


Also don't forget the Ihub Edu Channel.
~ http://investorshub.advfn.com/boards/education.aspx ~

[surf1944]

5:29AM Sinovac Biotech files New Drug Application for EV71 vaccine and receives filing acceptance from Beijing Drug Administration (SVA) 3.87 : Co announces its new drug application for its proprietary EV71 vaccine has been filed and accepted by the Beijing Drug Administration. In terms of next steps for the NDA review process in China, the Beijing Drug Administration will conduct an on-site inspection on the circumstances of Sinovac's clinical trials and submit its on-site inspection opinion along with the application documentations to Centers for Drug Evaluation of China Food and Drug Administration for further review and evaluation.

In parallel, co's dedicated EV71 vaccine manufacturing facility has been completed and is ready for the GMP inspection by CFDA.

[surf1944]

6:33AM On The Wires (WIRES) : Sinovac Biotech (SVA) announced that Sinovac Beijing, the main operating subsidiary co of Sinovac, obtained the Certificate of Good Manufacturing Practices for Pharmaceutical Products from the China State and Food Administration for its proprietary vaccines, its Haidian district bulk production plants, and its Changping filing and packaging facility. The GMP certificate is valid for five years starting from April 17, 2013.

[rawman]

This announcement makes it look pretty positive for the future, but the .10 per share miss, which was announced today, will constrain growth in the share price. I've been in and out of SVA many times over the last five years. It's troubling that they just can't seem to manage costs and pricing to the extent it will deliver a positive financial result. Maybe the EV71 will be the answer. This morning I exited at $3.96 and will sit on the side for awhile.

[surf1944]

7:18AM Sinovac Biotech EV71 vaccine Phase III top-line results presented at 13th Annual World Vaccine Congress & Expo; data indicated that our EV71 vaccine had 95% efficacy against EV71-associated HFMD /herpangina, and 100% efficacy against EV71-associated hospitalization (SVA) 4.13 : Co announced that Fengcai Zhu, Deputy Director of the Jiangsu Provincial Center for Disease Prevention and Control, presented data regarding Sinovac's proprietary enterovirus 71 ("EV71") vaccine against hand, foot and mouth disease ("HFMD") at the 13th Annual World Vaccine Congress & Expo, taking place from April 16-18, 2013, in Washington D.C. Dr. Fengcai Zhu acted as a co-principal investigator in Sinovac's phase III trial for its EV71 vaccine.

[gltaihub]

Bird Flu Surge in China Spurs H7N9 Pandemic Vaccine Preparations

http://www.bloomberg.com/news/2013-04-15/bird-flu-surge-in-china-spurs-h7n9-pandemic-vaccine-preparations.html

[diannedawn]

and once again... it's the stock with hardly any followers
that's a winner.

Is there some way you can scan ihub for the boards with the least followers?

:)

For me it's been a great indicator of what to buy!

[gltaihub]

WOW!!!! SVA Looking great!!!!SVA is going to be big time NOW.... good luck all

[surf1944]

6:38AM Sinovac Biotech reports preliminary top-line results from Phase III clinical trial for EV71 vaccine candidate against hand, foot and mouth disease; results demonstrate vaccine efficacy rate of 95.4% (SVA) 3.19 : Co announced preliminary top-line data from its Phase III clinical trial assessing the efficacy, immunogenicity and safety of the co's proprietary Enterovirus 71 ("EV71") vaccine against hand, foot and mouth disease ("HFMD"). The primary objective of the study was to evaluate the efficacy of the EV71 vaccine in the prevention of HFMD caused by EV71 in infants of 6 to 35 months old. The preliminary Phase III data showed that Sinovac's EV71 vaccine was 95.4% (95% CI: 87.5%, 98.3%) efficacious against HFMD caused by EV71. The Phase III trial showed good immunogenicity and safety for Sinovac's EV71 vaccine. The overall incidence of serious adverse events in this trial was 2.2% among the EV71 candidate vaccine recipients and 2.6% among those receiving a control vaccine during the fourteen months observation period. The difference in rates of serious adverse events ("SAEs") is not statistically significant. Most of the SAEs were considered unlikely to be vaccine-related.

[dannie30]

sva looks very good imo. i hope 2013 will be a good year for them.

[surf1944]

Breaking the recent trading high, still trending higher...

[surf1944]

Buying back into SVA, should be set for a nice EOY up move....

[little pig]

moved today

[surf1944]

8:04AM Sinovac Biotech receives tenders in Beijing and Shanghai to supply inactivated Hepatitis A vaccine healive under expanded immunization program (SVA) 2.49 : Co announced that it has been selected by the Beijing Health Bureau and the Shanghai Centers for Disease Control and Prevention to supply the Company's inactivated hepatitis A vaccine, Healive, to the Expanded Program of Immunization for each city. The tenders awarded to Sinovac in Beijing and Shanghai are valued at ~20 mln RMB and 13 million RMB, respectively. The vaccine purchased by the Beijing Health Bureau will be administered over a two year period to the pediatric population across the city. The vaccine purchased by the Shanghai CDC is for the 2012 pediatric population inoculation program.

[surf1944]

8:01AM Sinovac Biotech receives GMP certification for mumps vaccine production facility; On track to commence commercial production in Q3 2012 (SVA) 2.25 : Co announced today that it has received GMP certification from the China State Food and Drug Administration (SFDA) for the Company's dedicated mumps vaccine production plant at its Sinovac Dalian facility. The SFDA issued a public announcement on September 12, 2012, stating that the Good Manufacturing Practices certification was issued to Sinovac with the certificate number CN20120080.

The SFDA issued a public notification in July 2012 stating that Sinovac Dalian's mumps vaccine production plant is in compliance with the new GMP guidelines (2010 version) following the site inspection and documentation review. The Co obtained the production license from the SFDA for its mumps vaccine in Dec 2011. Sinovac continues to anticipate that it will be in a position to commence commercial production of the mumps vaccine in Q3 2012 and is on track to launch the mumps vaccine in China following the batch release process

[surf1944]

8:07AM Sinovac Biotech receives Beijing CDC tender award to supply seasonal flu vaccine Anflu to Beijing Citizens (SVA) 2.16 : The Beijing CDC plans to order up to a total of 1.8 million doses of seasonal flu vaccine in 2012 for the vaccination campaign from four vaccine manufacturers. The total quantity of vaccine doses to be supplied will depend on the actual demand in Beijing. Delivery is expected to commence during the third quarter of 2012. In 2011, total about 360,000 doses of Anflu were inoculated to the target population for the vaccination campaign in Beijing. According to public data as of November 22, 2011, over 1.3 million doses of seasonal flu vaccines were inoculated in Beijing, inclusive of the target population covered by the free vaccination campaign.